D
Tharimmune, Inc. THAR
$2.37 $0.010.42% NASDAQ
Recommendation
Prev Close
$2.36
Volume
819
Avg Vol (90D)
7,926,068
Market Cap
$82.71M
Dividend & Yield
--
52-Week Range
$0.95 - $9.08
P/E (TTM)
--
EPS (TTM)
-$4.11
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Tharimmune (NASDAQ:THAR) Shares Up 8.9% - What's Next?
11/22/2025 - MarketBeat
Retail Traders Left Exposed in High-Stakes Crypto Treasury Deals
11/14/2025 - Slashdot
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory ...
11/13/2025 - GuruFocus
Tharimmune (THAR) Gains FDA Support for TH104 Advanced Modeling Plan
11/13/2025 - GuruFocus
Tharimmune's TH104 receives positive feedback from FDA
11/13/2025 - The Fly
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
11/13/2025 - PR Newswire
Tharimmune Closes $545M Private Placement for Blockchain Strategy
11/7/2025 - TipRanks Financial Blog
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
11/6/2025 - GuruFocus
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
11/6/2025 - PR Newswire
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and ...
11/3/2025 - GuruFocus
Tharimmune (THAR) Secures $540M in Private Placement Funding
11/3/2025 - GuruFocus
Tharimmune announces $540M private placement
11/3/2025 - TipRanks Financial Blog
Tharimmune announces $540M private placement
11/3/2025 - The Fly
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
11/3/2025 - PR Newswire
Tharimmune Decline Means Insider Profits Down To US$83k
10/23/2025 - Simply Wall St
Tharimmune, Inc. (NASDAQ:THAR) Sees Significant Increase in Short Interest
10/19/2025 - Ticker Report
Tharimmune files to sell 327K shares of common stock for holders
10/17/2025 - TipRanks Financial Blog
Tharimmune files to sell 327K shares of common stock for holders
10/17/2025 - The Fly
Tharimmune Amends Warrants Agreement to Boost Liquidity
10/6/2025 - TipRanks Financial Blog
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 79.5%
10/3/2025 - Ticker Report
Critical Contrast: Tharimmune (NASDAQ:THAR) and Roivant Sciences (NASDAQ:ROIV)
9/15/2025 - Ticker Report
Tharimmune Achieves Nasdaq Compliance, Stabilizing Market Position
9/5/2025 - TipRanks Financial Blog
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
9/4/2025 - Globe Newswire
Promising Water Stocks To Research - August 25th
8/27/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$10.34M
Net Income (TTM)
-$10.32M
Balance Sheet
Total Assets (Q)
$7.70M
Total Debt (Q)
$195.50K
Total Liabilities (Q)
$1.54M
Book Value Per Share (Q)
$0.854
Cash Flow
Cash from Operations (TTM)
-$8.72M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$11.56M
Net Change in Cash (TTM)
$2.84M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
-0.13
7-Day Total Return
5.33%
30-Day Total Return
-25.00%
60-Day Total Return
-19.93%
90-Day Total Return
58.63%
Year to Date Total Return
15.61%
1-Year Total Return
7.24%
2-Year Total Return
-78.39%
3-Year Total Return
-98.70%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $0.95
52-week High
Aug 25, 2025 - $9.08
Valuation
Market Cap
$82.71M - Micro Cap
Enterprise Value
$75.29M
Price/Sales (TTM)
--
Price/Book (Q)
2.76
Dividends and Shares
Shares Outstanding
6.24
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tharimmune.com
Phone Number
732-889-3111
Address
34 Shrewsbury Avenue
Red Bank, NJ 07701
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed